# US 2006/0153798 A1 · Methods and compositions for needleless delivery of macromolecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153798 A1
- Document ID: US20060153798A1
- Status: Published application
- Kind: A1
- Application number: 11/244,349
- Filed: 2005-10-04
- Published: 2006-07-13
- Earliest claimed: 2004-10-04
- Assignees: Trinity Biosystems, Inc.
- Inventors: Randall Mrsny
- Web page: https://patentgrep.com/patent/US20060153798A1

## CPC

- A61K 38/212: {IFN-alpha}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- C07K 2319/50: containing protease site
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods and compositions for needleless delivery of macromolecules to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a macromolecule to be delivered to a subject, and a cleavable linker. In certain aspects, the cleavable linker can be cleavable by an enzyme present in higher concentration at or near the basal-lateral membrane of a polarized epithelial cell or in the plasma than elsewhere in the body, for example, at the apical side of the polarized epithelial cell. In other aspects, the invention provides nucleic acids encoding delivery constructs of the invention, kits comprising delivery constructs of the invention, cells expressing delivery constructs of the invention, and methods of using delivery constructs of the invention.

## Claims

### Claim 1

A delivery construct, comprising:
a)—a receptor binding domain,
b)—a transcytosis domain,
c)—a macromolecule to be delivered to a subject, and
d)—a cleavable linker,
wherein cleavage at said cleavable linker separates said macromolecule from the remainder of said construct, and wherein said cleavable linker is cleavable by an enzyme that i) exhibits greater activity at a basal-lateral membrane of a polarized epithelial cell of said subject than at an apical membrane of the polarized epithelial cell, or ii) exhibits greater activity in the plasma of said subject than at an apical membrane of the polarized epithelial cell of the subject.

### Claim 2 (depends on 1)

The delivery construct of claim 1, further comprising a second cleavable linker.

### Claim 3 (depends on 1)

The delivery construct of claim 1, wherein said cleavable linker comprises an amino acid sequence that is selected from the group consisting of Ala-Ala-Pro-Phe (SEQ ID NO.:4), Gly-Gly-Phe (SEQ ID NO.:5), Ala-Ala-Pro-Val (SEQ ID NO.:6), Gly-Gly-Leu (SEQ ID NO.:7), Ala-Ala-Leu (SEQ ID NO.:8), Phe-Val-Arg (SEQ ID NO.:9), Val-Gly-Arg (SEQ ID NO.:10).

### Claim 4 (depends on 1)

The delivery construct of claim 1, wherein said enzyme that is present at a basal-lateral membrane of a polarized epithelial cell is selected from the group consisting of Cathepsin GI, Chymotrypsin I, Elastase I, Subtilisin AI, Subtilisin AII, Thrombin I, and Urokinase I.

### Claim 5 (depends on 1)

The delivery construct of claim 1, wherein said receptor binding domain is selected from the group consisting of receptor binding domains from Pseudomonas exotoxin A, cholera toxin, botulinum-toxin, diptheria toxin, shiga toxin, or shiga-like toxin; monoclonal antibodies; polyclonal antibodies; single-chain antibodies; TGF α; EGF; IGF-I; IGF-II; IGF-III; IL-1; IL-2; IL-3; IL-6; MIP-1a; MIP-1b; MCAF; and IL-8.

### Claim 6 (depends on 1)

The delivery construct of claim 1, wherein said receptor binding domain binds to a cell-surface receptor that is selected from the group consisting of α2-macroglobulin receptor, epidermal growth factor receptor, transferrin receptor, chemokine receptor, CD25, CD11B, CD11C, CD80, CD86, TNFα receptor, TOLL receptor, M-CSF receptor, GM-CSF receptor, scavenger receptor, and VEGF receptor.

### Claim 7 (depends on 5)

The delivery construct of claim 5, wherein said receptor binding domain of Pseudomonas exotoxin A is Domain Ia of Pseudomonas exotoxin A.

### Claim 8 (depends on 7)

The delivery construct of claim 7, wherein said receptor binding domain of Pseudomonas exotoxin A has an amino acid sequence that is SEQ ID NO.:11.

### Claim 9 (depends on 1)

The delivery construct of claim 1, wherein said transcytosis domain is selected from the group consisting of transcytosis domains from Pseudomonas exotoxin A, botulinum toxin, diptheria toxin, pertussis toxin, cholera toxin, heat-labile E. coli enterotoxin, shiga toxin, and shiga-like toxin.

### Claim 10 (depends on 9)

The delivery construct of claim 9, wherein said transcytosis domain is Pseudomonas exotoxin A transcytosis domain.

### Claim 11 (depends on 10)

The delivery construct of claim 10, wherein said Pseudomonas exotoxin A transcytosis domain has an amino acid sequence that is SEQ ID NO.:2.

### Claim 12 (depends on 1)

The delivery construct of claim 1, wherein said macromolecule is selected from the group of a nucleic acid, a peptide, a polypeptide, a protein, and a lipid.

### Claim 13 (depends on 12)

The delivery construct of claim 12, wherein said polypeptide is selected from the group consisting of polypeptide hormones, cytokines, chemokines, growth factors, and clotting factors.

### Claim 14 (depends on 13)

The delivery construct of claim 13, wherein said polypeptide is selected from the group consisting of IGF-I, IGF-II, IGF-III, EGF, IFN-α, IFN-β, IFN-γ, G-CSF, GM-CSF, IL-1, IL-2, IL-3, IL-6, IL-8, IL-12, EPO, growth hormone, factor VII, vasopressin, calcitonin, parathyroid hormone, luteinizing hormone-releasing factor, tissue plasminogen activators, proinsulin, insulin, glucocorticoid, amylin, adrenocorticototropin, enkephalin, and glucagon-like peptide 1.

### Claim 15 (depends on 14)

The delivery construct of claim 14, wherein said polypeptide is human growth hormone.

### Claim 16 (depends on 12)

The delivery construct of claim 12, wherein said protein is human insulin.

### Claim 17 (depends on 12)

The delivery construct of claim 12, wherein said protein is human IFN-α.

### Claim 18 (depends on 12)

The delivery construct of claim 12, wherein said protein is human IFN-α2b.

### Claim 19 (depends on 12)

The delivery construct of claim 12, wherein said protein is human proinsulin.

### Claim 20 (depends on 12)

The delivery construct of claim 12, further comprising a second macromolecule that is selected from the group of a nucleic acid, a peptide, a polypeptide, a protein, a lipid, or a small organic molecule and a second cleavable linker, wherein cleavage at said second cleavable linker separates said second macromolecule from the remainder of said construct.

### Claim 21 (depends on 17)

The delivery construct of claim 17, wherein said macromolecule is a first polypeptide and said second macromolecule is a second polypeptide.

### Claim 22 (depends on 21)

The delivery construct of claim 21, wherein said first polypeptide and said second polypeptide associate to form a multimer.

### Claim 23 (depends on 22)

The delivery construct of claim 22, wherein said multimer is a dimer, tetramer, or octamer.

### Claim 24 (depends on 23)

The delivery construct of claim 23, wherein said dimer is an antibody.

### Claim 25

A polynucleotide that encodes a delivery construct, said delivery construct comprising:
a)—a receptor binding domain,
b)—a transcytosis domain,
c)—a macromolecule to be delivered to a subject, and
d)—a cleavable linker,
wherein cleavage at said cleavable linker separates said macromolecule from the remainder of said construct, and wherein said cleavable linker is cleavable by an enzyme that i) exhibits greater activity at a basal-lateral membrane of a polarized epithelial cell of said subject than at an apical membrane of the polarized epithelial cell, or ii) exhibits greater activity in the plasma of said subject than at an apical membrane of the polarized epithelial cell of the subject.

### Claim at position 26

-41. (canceled)

### Claim 42

A polynucleotide that encodes a delivery construct, said polynucleotide comprising:
a)—a nucleic acid sequence encoding a receptor binding domain,
b)—a nucleic acid sequence encoding a transcytosis domain,
c)—a nucleic acid sequence encoding a cleavable linker, and
d)—a nucleic acid sequence comprising a polylinker insertion site,
wherein said polylinker insertion site is oriented relative to said nucleic acid sequence encoding a cleavable linker to allow to cleavage of the cleavable linker to separate a macromolecule that is encoded by a nucleic acid inserted into said polylinker insertion site from the remainder of said delivery construct, and wherein said cleavable linker is cleavable by an enzyme that i) exhibits greater activity at a basal-lateral membrane of a polarized epithelial cell of said subject than at an apical membrane of the polarized epithelial cell, or ii) exhibits greater activity in the plasma of said subject than at an apical membrane of the polarized epithelial cell of the subject.

### Claim 43 (depends on 25)

An expression vector comprising the polynucleotide of claim 25.

### Claim 44 (depends on 43)

A cell comprising the expression vector of claim 43.

### Claim 45

A composition comprising a delivery construct, said delivery construct comprising:
a)—a receptor binding domain,
b)—a transcytosis domain,
c)—a macromolecule to be delivered to a subject, and
d)—a cleavable linker,
wherein said cleavable linker is cleavable by an enzyme that i) exhibits greater activity at a basal-lateral membrane of a polarized epithelial cell of said subject than at an apical membrane of the polarized epithelial cell, or ii) exhibits greater activity in the plasma of said subject than at an apical membrane of the polarized epithelial cell of the subject.

### Claim 46 (depends on 45)

The composition of claim 45, wherein said composition further comprises a pharmaceutically acceptable diluent, excipient, vehicle, or carrier.

### Claim 47 (depends on 45)

The composition of claim 45, wherein said composition is formulated for nasal or oral administration.

### Claim 48

A method for delivering a macromolecule to a subject, comprising contacting an apical surface of a polarized epithelial cell of the subject with a delivery construct, wherein said delivery construct comprises a receptor binding domain, a transcytosis domain, a cleavable linker, and the macromolecule, wherein the transcytosis domain transcytoses the macromolecule to and through the basal-lateral membrane of said epithelial cell, wherein cleavage at said cleavable linker separates said macromolecule from the remainder of said construct, and wherein said cleavable linker is cleavable by an enzyme that i) exhibits greater activity at a basal-lateral membrane of a polarized epithelial cell of said subject than at an apical membrane of the polarized epithelial cell, or ii) exhibits greater activity in the plasma of said subject than at an apical membrane of the polarized epithelial cell of the subject, and wherein cleavage at the cleavable linker separates the macromolecule from the remainder of the delivery construct, thereby delivering the macromolecule to the subject.

### Claim at position 34

-57. (canceled)

### Claim 58 (depends on 1)

A method for delivering a macromolecule to the bloodstream of a subject, comprising contacting the delivery construct of claim 1 to an apical surface of a polarized epithelial cell of the subject, such that the macromolecule is delivered to the bloodstream of the subject, wherein a lower titer of antibodies specific for the macromolecule is induced in the serum of the subject than is induced by subcutaneously administering the macromolecule to a subject separately from the remainder of the delivery construct.

### Claim at position 36

-68. (canceled)
